Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Daniel C. Baumgart, Catherine Le Berre
New England Journal of Medicine (2021) Vol. 385, Iss. 14, pp. 1302-1315
Closed Access | Times Cited: 243

Showing 1-25 of 243 citing articles:

Ulcerative Colitis in Adults
Beatriz Gros, Gilaad G. Kaplan
JAMA (2023) Vol. 330, Iss. 10, pp. 951-951
Closed Access | Times Cited: 253
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
Edward V. Loftus, Julián Panés, Ana P. Lacerda, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 21, pp. 1966-1980
Closed Access | Times Cited: 238
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Geert R. D’Haens, Marla C. Dubinsky, Taku Kobayashi, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 26, pp. 2444-2455
Open Access | Times Cited: 152
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Bram Verstockt, Azucena Salas, Bruce E. Sands, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 109
Lactobacillus johnsonii alleviates colitis by TLR1/2-STAT3 mediated CD206 + macrophages IL-10 activation
Dingjiacheng Jia, Qiwen Wang, Yingying Hu, et al.
Gut Microbes (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 96
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
Juan Liu, Bin Di, Lili Xu
Cytokine & Growth Factor Reviews (2023) Vol. 71-72, pp. 1-12
Closed Access | Times Cited: 73
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
Dongze Wu, Yingzhao Jin, Yuhan Xing, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102193-102193
Open Access | Times Cited: 66
An Orally-Administered Nanotherapeutics with Carbon Monoxide Supplying for Inflammatory Bowel Disease Therapy by Scavenging Oxidative Stress and Restoring Gut Immune Homeostasis
Xu Zhang, Zhang Yuan, Jianshuang Wu, et al.
ACS Nano (2023) Vol. 17, Iss. 21, pp. 21116-21133
Closed Access | Times Cited: 63
Edible exosome-like nanoparticles from portulaca oleracea L mitigate DSS-induced colitis via facilitating double-positive CD4+CD8+T cells expansion
Min‐zheng Zhu, Haoming Xu, Yujie Liang, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 57
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Tommaso Lorenzo Parigi, Ferdinando D’Amico, María T. Abreu, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 853-859
Closed Access | Times Cited: 51
A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation
Ziqi Ma, Tao Zuo, Norbert Frey, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Western diets and chronic diseases
Timon E. Adolph, Herbert Tilg
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2133-2147
Closed Access | Times Cited: 23
Microbiota therapeutics for inflammatory bowel disease: the way forward
Lukas Bethlehem, María Manuela Estevinho, Ari Grinspan, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 5, pp. 476-486
Open Access | Times Cited: 22
Lactobacillus rhamnosus GG induces STING-dependent IL-10 in intestinal monocytes and alleviates inflammatory colitis in mice
Wei Si, Xin Zhao, Ruitong Li, et al.
Journal of Clinical Investigation (2025) Vol. 135, Iss. 3
Open Access | Times Cited: 2
Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images
Reed T. Sutton, Osmar R. Zäıane, Randolph G. Goebel, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 66
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Virginia Solitano, Antonio Facciorusso, Tine Jess, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 4, pp. 907-921.e2
Closed Access | Times Cited: 60
Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019
Yang Zhang, Jiali Liu, Xiao Han, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 56
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
Christopher Ma, Jurij Hanžel, Remo Panaccione, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 950-964
Open Access | Times Cited: 55
Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease
Defeng Li, Meifeng Yang, Jing Xu, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 3893-3911
Open Access | Times Cited: 41
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson, Maria Barsky, Waseem Ahmed, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 2, pp. 317-328
Closed Access | Times Cited: 41
Development of Spleen Targeting H2S Donor Loaded Liposome for the Effective Systemic Immunomodulation and Treatment of Inflammatory Bowel Disease
Chiwoo Oh, Wooseung Lee, Jeongbin Park, et al.
ACS Nano (2023) Vol. 17, Iss. 5, pp. 4327-4345
Closed Access | Times Cited: 40
Management of inflammatory bowel diseases in older adults
Siddharth Singh, Brigid S. Boland, Tine Jess, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 4, pp. 368-382
Open Access | Times Cited: 38
The global, regional, and national burden of inflammatory bowel diseases, 1990–2019: A systematic analysis for the global burden of disease study 2019
Jihye Park, Gwang Hun Jeong, Minjin Song, et al.
Digestive and Liver Disease (2023) Vol. 55, Iss. 10, pp. 1352-1359
Closed Access | Times Cited: 34
Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study
Xuejie Chen, Xin Xiang, Weitong Xia, et al.
Journal of Epidemiology and Global Health (2023) Vol. 13, Iss. 4, pp. 725-739
Open Access | Times Cited: 28
iPSC-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions
Janis Kerkering, Bakhrom Muinjonov, Kamil Rosiewicz, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top